Zero Candida Technologies Announces DTC Eligibility and to Present at OTCQB Venture Virtual Investor Conference on August 7th

Rhea-AI Summary

Zero Candida Technologies (OTCQB: ZCTFF), a FemTech medical device company, has announced two key developments: achieving DTC eligibility for its common shares and an upcoming presentation at the OTCQB Venture Virtual Investor Conference on August 7th, 2025.

The DTC eligibility enables electronic clearing and settlement of shares in the United States, improving trading efficiency and reducing settlement times. This development aims to enhance liquidity and reduce transaction costs while making shares more accessible to U.S. investors, particularly institutions requiring DTC eligibility.

Positive

• DTC eligibility achieved, enhancing trading efficiency and liquidity for U.S. investors
• Increased accessibility to institutional investors through DTC eligibility
• Broader investor exposure through OTCQB Venture Virtual Investor Conference participation

Negative

• None.

VANCOUVER, BC, Aug. 5, 2025 /PRNewswire/ -- Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the "Company" or "ZCT"), a FemTech medical device company revolutionizing women's health, is pleased to announce that its common shares are now eligible for Depository Trust Company ("DTC") electronic clearing and settlement services. Additionally, the Company will present live at the OTCQB Venture Virtual Investor Conference hosted by VirtualInvestorConferences.com on August 7th, 2025.

 

Eli Ben Haroosh, Founder and CEO of ZCT, commented: "Achieving DTC eligibility represents a significant advancement in our capital markets strategy, providing enhanced liquidity and accessibility for our U.S. investors. Combined with our participation in the upcoming OTCQB Venture Virtual Investor Conference, we are positioned to reach a broader institutional and retail investor audience as we unlock value through AI-driven medical technology."

DTC Eligibility Benefits DTC eligibility enables electronic clearing and settlement of Zero Candida's common shares in the United States, significantly improving trading efficiency and reducing settlement times for investors. This development is expected to enhance liquidity, reduce transaction costs, and make the Company's shares more accessible to a wider range of U.S. investors, including institutions that require DTC eligibility for investment consideration.

Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings, and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

The OTCQB Venture Market, operated by OTC Markets Group and recognized by the U.S. Securities and Exchange Commission (SEC), is a leading marketplace for early- and development-stage U.S. and international companies. The OTCQB has demonstrated its effectiveness in helping companies build shareholder value and achieve fair valuation through enhanced transparency and liquidity. To find real-time quotes and market information on Zero Candida, visit www.otcmarkets.com

About Zero Candida Technologies

Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) is a publicly traded FemTech company pioneering innovative solutions to address unmet needs in women's health. The company is developing a tampon-like device that uses artificial intelligence and therapeutic blue light at a precise wavelength and intensity to effectively treat Candida fungus, with a proven 99.999% success rate in POC. Vulvo-Vaginal Candidiasis (VVC) affects approximately 75% of women worldwide, and recurrent cases (four or more episodes per year) are increasingly resistant to existing drug treatments, as the root cause remains poorly understood and inadequately addressed.

ZCT is following a de novo regulatory pathway and is preparing for an upcoming clinical trial after successfully completing a safety trial in large animals (sheep). The Company has secured funding and partnerships with leading hospitals in Europe and Israel, and is expanding its global patent portfolio, with applications filed in the United States, Brazil, and Europe, and a full patent already granted in South Africa. With the VVC treatment market projected to exceed USD $2B in the next five years, ZCT is combining hybrid medicine and technology-based diagnostics to improve access to underserved populations and bring gynecology into the 21st century. To learn more, visit www.zero-candida.com

Forward-Looking Statements

This news release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, are forward-looking statements. The Company provides no assurance that forward-looking statements and information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements or information. Accordingly, readers should not place undue reliance on forward-looking statements or information. The Company does not undertake to update any forward-looking statements, other than as required by law. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by Zero Candida. Readers are cautioned not to place undue reliance on forward-looking statements.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Company Contacts:
Eli Ben Haroosh
CEO & Founder
info@zero-candida.com

Victoria Gamble
investors@zero-candida.com
(647) 874 3767

Logo: https://mma.prnewswire.com/media/2420533/5146953/ZERO_CANDIDA_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/zero-candida-technologies-announces-dtc-eligibility-and-to-present-at-otcqb-venture-virtual-investor-conference-on-august-7th-302521817.html

SOURCE Zero Candida

FAQ

What does DTC eligibility mean for Zero Candida Technologies (ZCTFF) investors?

DTC eligibility enables electronic clearing and settlement of ZCTFF shares in the U.S., improving trading efficiency, reducing settlement times, and lowering transaction costs for investors.

When is Zero Candida Technologies (ZCTFF) presenting at the OTCQB Venture Virtual Investor Conference?

Zero Candida Technologies will present live at the OTCQB Venture Virtual Investor Conference on August 7th, 2025.

Who will be presenting for Zero Candida Technologies (ZCTFF) at the investor conference?

Eli Ben Haroosh, the Founder and CEO of Zero Candida Technologies, will be presenting at the conference.

What is Zero Candida Technologies' (ZCTFF) business focus?

Zero Candida Technologies is a FemTech medical device company focused on revolutionizing women's health through AI-driven medical technology.

Where can investors find real-time quotes for Zero Candida Technologies (ZCTFF)?

Investors can find real-time quotes and market information for ZCTFF on www.otcmarkets.com.